tradingkey.logo

Bausch + Lomb Corp

BLCO
View Detailed Chart

15.190USD

-0.190-1.24%
Close 09/19, 16:00ETQuotes delayed by 15 min
5.37BMarket Cap
LossP/E TTM

Bausch + Lomb Corp

15.190

-0.190-1.24%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.24%

5 Days

0.00%

1 Month

+3.97%

6 Months

-1.94%

Year to Date

-15.89%

1 Year

-24.05%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
62 / 207
Overall Ranking
143 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 13 analysts
Hold
Current Rating
15.373
Target Price
-0.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 27.15% year-on-year.
Fairly Valued
The company’s latest PE is -19.68, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 350.71M shares, decreasing 5.16% quarter-over-quarter.
Held by Carl Icahn
Star Investor Carl Icahn holds 3.50M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Ticker SymbolBLCO
CompanyBausch + Lomb Corp
CEOMr. Brenton L. (Brent) Saunders, J.D.
Websitehttps://ir.bausch.com/
KeyAI